Disclosure of Financial Relationships
The American Journal of Psychiatry requires its editors to disclose any fi nancial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:
| •. | Robert Freedman, M.D., reports no financial relationships with commercial interests. | ||||
| •. | David A. Lewis, M.D., received investigator-initiated research support from the BMS Foundation, Bristol-Myers Squibb, Curridium Ltd., and Pfizer. He has served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science. | ||||
| •. | Robert Michels, M.D., reports no financial relationships with commercial interests. | ||||
| •. | Daniel S. Pine, M.D., reports no financial relationships with commercial interests. | ||||
| •. | Susan K. Schultz, M.D., has received research support from the Alzheimer's Disease Cooperative Study for a project conducted in partnership with Baxter Healthcare. | ||||
| •. | Carol A. Tamminga, M.D., has served on advisory boards for Acadia Pharmaceuticals and Intracellular Therapies; has served as a consultant for Astellas, Cypress Bioscience, Eli Lilly, PureTech Ventures, and Sunovion; and served as an expert witness for Finnegan Henderson Farabow Garrett & Dunner, LLP. | ||||
